Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-128 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TAK-128 5 mg QD | EXPERIMENTAL | - |
| TAK-128 50 mg QD | EXPERIMENTAL | - |
| TAK-128 100 mg QD | EXPERIMENTAL | - |
| Placebo QD | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TAK-128 | DRUG | TAK-128 5 mg, tablets, orally, once daily for up to 6 months. |
| Placebo | DRUG | TAK-128 placebo-matching tablets, orally, once daily for up to 6 months. |
Inclusion Criteria: * Female subjects of childbearing potential must be nonpregnant, nonlactating and on an acceptable form of contraception. * The subject has fasting clinical laboratory evaluations within the normal reference range for the testing laboratory, or if not, the results must be deemed...
TAK-128 is an investigational small molecule being studied for the treatment of diabetic neuropathies, specifically diabetic peripheral neuropathy. It is a Phase 2 drug candidate developed by Takeda Pharmaceutical Company Limited. The drug is not approved and remains in clinical development.
The molecular target of TAK-128 has not been disclosed in available information. It is a small molecule being investigated for diabetic peripheral neuropathy, but its specific mechanism of action is not publicly detailed.
TAK-128 is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol TAK. The drug is currently in Phase 2 clinical development for diabetic neuropathies.
TAK-128 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it is not FDA approved. The drug remains investigational and has not yet advanced to Phase 3 or received regulatory approval.
TAK-128 has one completed clinical trial, NCT00229437, titled 'Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy.' This Phase 2, randomized, double-blind, placebo-controlled study enrolled 343 participants in the United States and Canada.
No alternative names for TAK-128 have been disclosed. The drug is known only by its development code TAK-128, and no other brand or chemical names have been publicly associated with it.